Tag: Glioblastoma Multiforme

October 1, 2019

Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100

Cardiol Therapeutics Inc., announces that it has completed the manufacturing scale-up for commercialization of its CardiolRx™100 CBD formulation.
September 5, 2019

Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th

Cardiol Therapeutics Inc. (TSX:CRDL, OTCQX:CRTPF) President & CEO David Elsley will present live at the KCSA Cannabis Investor Conference on...
March 28, 2019

Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A

Cardiol Therapeutics Inc. (TSX:CRDL) ("Cardiol" or the "Company"), a leader in the research and development of pharmaceutical cannabidiol and targeted...
March 12, 2019

Cardiol Therapeutics to Present at the 2019 LD Micro Virtual Conference

Cardiol Therapeutics Inc. (TSX:CRDL) (OTC:CRTPF), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for...
March 6, 2019

Cardiol Therapeutics Appoints Thomas Moffatt as Chief Commercial Officer

Cardiol Therapeutics Inc. (TSX: CRDL) is pleased to announce the appointment of Thomas (Tom) Moffatt, BBA, as Chief Commercial Officer.
January 18, 2019

Cardiol Therapeutics Inc. Closes Over-Allotment

Cardiol Therapeutics Inc. (TSX:CRDL)  ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products...
December 20, 2018

Cardiol Therapeutics Completes Initial Public Offering and the Company’s Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols “CRDL” and “CRDL.WT”

Cardiol Therapeutics Inc. (TSX:CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products...